Phase 3 Trial of Fablyn Plus Verzenio for Metastatic Breast Cancer Initiates Registration
March 20th 2023Pre- and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation are eligible to participate in the next round of Fablyn’s upcoming clinical trial.
First Patients Dosed With Novel Inhibitor in Trial on Relapsed or Refractory AML Subset
February 11th 2023Researchers conducting a phase 2 trial recently dosed the first patients with a novel menin inhibitor for the treatment of patients with NPM1-mutant relapsed or refractory acute myeloid leukemia.
Researchers Hope a New Drug Can Help Overcome Immunotherapy Resistance in Metastatic Cancers
December 2nd 2022A recently launched clinical trial of NTX1088 will determine if the novel drug can help overcome immune checkpoint inhibition resistance in patients with locally advanced or metastatic solid tumors.